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Objectives:  The  authors  present  the guidelines  of  the French  Otorhinolaryngology  –  Head  and  Neck
Surgery  Society  (SFORL)  for  patient  pathway  organization  in head  and  neck  cancer,  and  in particular  for
multidisciplinary  team  meetings.  The  present  article  concerns  the therapeutic  decision-making  process.
Methods: A  multidisciplinary  work group  was  entrusted  with  a review  of  the scientiﬁc  literature  on
the  above  topic.  Guidelines  were  drawn  up, based  on  the  articles  retrieved  and  the  group  members’
individual  experience.  They  were  then  read  over  by  an  editorial  group  independent  of the work  group.
The  ﬁnal  version  was  established  in  a coordination  meeting.  The  guidelines  were  graded  as  A, B,  C  or
expert  opinion,  by  decreasing  level  of evidence.
Results: It is  recommended  that:  an  organ  specialist  should  contribute  to  all multidisciplinary  meetings
on  head  and  neck  cancer;  all members  of  the  multidisciplinary  meeting  should  have  speciﬁc  knowledge
in  head  and  neck cancer;  any  referring  physician  who  does  not  follow  the  multidisciplinary  meeting’s
advice  should  justify  that  decision;  there  should  be  sufﬁcient  time  to  prepare,  discuss  and  sum  up the
cases  dealt  with  in the  multidisciplinary  team  meeting.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.∗ Corresponding author.
E-mail address: sophie.deneuve@lyon.unicancer.fr (S. Deneuve).
http://dx.doi.org/10.1016/j.anorl.2015.06.006
879-7296/© 2015 Elsevier Masson SAS. All rights reserved.1. Introduction
The therapeutic decision-making process comprises the vari-
ous stages, following discovery of tumor, leading to a coherent
treatment proposal by the medical and paramedical team to the
patient and family, who should at least partly adhere to the pro-
posal.
2 yngolo
t
F
p
r
a
M
h
•
•
•
d
c
m
g
o
g
s
d
f
t
g
b
f
2
l
•
•
•
a
p
e
a
t
t
s
w
a
s14 S. Deneuve et al. / European Annals of Otorhinolar
Multidisciplinary team meetings (MDTM) were made manda-
ory in France under a Circular from the Health Ministry dated
ebruary 22nd, 2005 [1], to bring together the patient’s ﬁle and
ropose treatment. At least 3 physicians of different specialties are
equired under the terms of the Circular, although it is often desir-
ble that a larger number of specialties should be represented. The
DTM is a therapeutic decision-making tool. A number of beneﬁts
ave been reported:
positive impact on tumor staging [2] (level of evidence: 4);
impact on decision-making and treatment modiﬁcation [3] (level
of evidence: 4): treatment as recommended by the MDTM tends
to be curative and more aggressive [4] (level of evidence: 4);
impact on the care pathway: the interval between ﬁrst consulta-
tion and treatment initiation is shortened [5] (level of evidence:
4).
A nationwide multidisciplinary work group was entrusted with
rawing up guidelines for the therapeutic decision-making pro-
ess in head and neck cancer. The French Health Authority (HAS)’s
ethodology of formalized expert consensus for good practice
uidelines (http://www.has-sante.fr) was followed. A pilot group
rganized the consensus conference logistics, choice of editorial
roup members, and analysis of the literature based on a PubMed
earch. Articles were graded A, B, C or expert opinion according
ecreasing level of evidence, in line with the National Agency
or Evaluation and Accreditation in Healthcare (ANAES)’s litera-
ure analysis and guidelines grading guide. A preliminary series of
uidelines was drawn up, based on a position paper, then assessed
y the editorial group, and recast by the work group following
eedback.
. Results
Guideline 1
An organ specialist (head and neck or maxillofacial sur-
geon) should attend all head and neck cancer MDTMs. Expert
opinion.
Guideline 2
All MDTM members should have speciﬁc knowledge in
head and neck cancer. Expert opinion.
The following factors are mandatory in MDTMs  [6] (HAS guide-
ine):
statement detailing organization and functioning;
minutes of each meeting, with list of those present;
predetermined schedule: at least twice monthly [7] (level of evi-
dence: 4).
All MDTM members should have speciﬁc knowledge of head
nd neck cancer and general oncology [8] (European guideline). The
resence of a specialist organ surgeon is desirable [9–11] (level of
vidence: 3).
Each patient ﬁle is presented by a physician, whether or not usu-
lly an MDTM member: a physician not regularly present may  come
o present a case or delegate an MDTM member, but it is preferable
hat the physician in charge of treatment or treatment coordination
hould be present. The person presenting the ﬁle should be familiar
ith the case and able to discuss it and answer the questions and
rguments of those present.
Files for patients with new primary or recurrence should be
ystematically presented, either for discussion or for treatmentgy, Head and Neck diseases 132 (2015) 213–215
validation [8] (European guideline). Each key step of treatment
should be dealt with in MDTM.  Possible inclusion in clinical trials is
also dealt with (interest of presence of a clinical research associate
or clinician).
Guideline 3
The MDTM should have sufﬁcient time to prepare, discuss
and sum up the cases presented. Expert opinion.
Ahead of the meeting, a standardized medical data form should
be ﬁlled out by the physician referring the case to the MDTM
[7] (HAS–INCA [National Cancer Institute] guideline). The medical
proposal must take account of the following factors, requisite to
decision-making:
• TNM classiﬁcation, essential before considering treatment: clas-
siﬁcation as local, regional or generalized;
• pathology data not included in TNM classiﬁcation. Certain pathol-
ogy results are of recognized interest in tumoral assessment:
thickness, certain histologic forms, expression of certain antigens,
etc;
• imaging ﬁle: usually, all examination results available will be
looked at during the meeting, as a ﬁnal check, which may reveal a
suspect element: metastasis, doubtful image, suspicion of second
tumor, etc;
• general health status and assessment of capacity to withstand
treatment: analysis of all complementary examinations per-
formed at initial assessment;
• opinion of patient’s usual physician, provided directly or reported
to a MDTM member. The patient’s own physician is aware of the
patient’s socioeconomic situation, capacities and support;
• epidemiological and social data: private and family life, support,
friends and relatives;
• the possible interest of the patient being present at the MDTM is
a matter of debate [12,13] (level of evidence: 4).
Guideline 4
If the advice of the MDTM is not followed by the referring
physician, the latter should justify that position. Expert opinion.
After examination of the various elements:
• either the ﬁle is sufﬁcient for therapeutic decision-making, and
discussion leads to a team opinion;
• or further examinations and/or consultations are needed and the
ﬁle is held over for consideration in a subsequent MDTM.
After free discussion in which each team member gives his or
her opinion, a consensus should emerge [14] (level of evidence: 4).
The MDTM report should include the date, treatment proposal and
names and qualiﬁcations of those present [6] (HAS guideline) and
be kept in the patient’s ﬁle [15] (HAS–INCA guideline: charge book
for oncology communication ﬁles). The treatment proposal is to be
based on the guidelines used by the MDTM.
Once the MDTM has come to a decision, implementation is to
be considered: referral to specialist consultations in oncology, radi-
ology, surgery, support cells and supporting care (physiotherapy,
nutrition, pain, psychology, social work). This enables the disease
to be considered globally, without adding to the anxiety inevitably
experienced by the patient and family, who often come up against
practical problems.
yngolo
m
p
t
p
f
b
m
f
d
a
e
3
t
r
v
R
[
[
[
[
[
[
[
[17] Badoual C, et al. [Pathologists and the French network of expertise on rareS. Deneuve et al. / European Annals of Otorhinolar
If the treatment implemented differs from the MDTM’s recom-
endation, the reasons should be put forward in writing by the
atient’s physician and included in the ﬁle [6] (HAS guideline).
The MDTM is intended to offer the patient the best adapted
reatment [8] (level of evidence: 4). This form of organization is
articularly useful in rare tumors. To meet INCA requirements
or expert center organization [16] (INCA guideline), a national
i-monthly back-up MDTM is held to deal with complex decision-
aking in rare head and neck tumors: the French Expert Network
or Rare Head and Neck Cancers (REFCOR) [17,18] (level of evi-
ence: 4).
The patient may  also wish to have other opinions on treatment,
nd this should be facilitated by providing the patient with all rel-
vant information.
. Conclusion
The MDTM is intended to offer the patient the best adapted
reatment, and should apply to all cases of new primary or recur-
ence and to each key step in treatment, either for discussion or for
alidation.
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